This article examines Western Union's ongoing efforts to transition from traditional remittances to digital payment methods in a rapidly evolving financial landscape. It explores how the company's strategic moves, financial stability, and competitive positioning will determine its future growth amidst pressure from fintech rivals. The piece also delves into regulatory challenges, valuation metrics, and the importance of digital adoption for long-term success.

Bristol-Myers Squibb Company (BMY) is listed among 15 cash-rich dividend stocks, despite a recent downgrade in its price recommendation by BofA analyst Jason Gerberry. The company anticipates diverse revenue for 2026, with growth in its portfolio countering declines in legacy products due to exclusivity losses. BMY projects strong growth for Eliquis in 2026 but expects a future drop in sales in 2027 due to patent expirations.

Truist Financial has increased its price target for Chord Energy (NASDAQ:CHRD) from $169 to $187, maintaining a 'buy' rating and indicating a potential upside of 38.51%. This decision is based on the energy company's strong operational and financial performance, particularly its solid Q4 2025 results and its focus on the Williston and Delaware Basins. Other analysts have also issued positive ratings, suggesting significant upside potential for Chord Energy's stock in the current energy market.

Wingstop Inc (WING) shares surged 3.6% to $186.31, with a GF Score of 86 out of 100, indicating strong overall performance. The stock's current price is 52.2% below its GF Value™ estimate of $389.82, suggesting it is significantly undervalued despite recent declines and insider selling. Investors are advised to conduct due diligence, considering the attractive valuation against recent market performance and insider activity.

NextEra Energy (NEE) saw its stock price drop 1.9% to $92.33 on Monday, with trading volume significantly below average. Despite this, Wall Street maintains a "Moderate Buy" consensus rating with an average price target of $94.94, and some analysts have even higher targets. The company beat EPS estimates for its last quarter, but missed revenue expectations, and raised its quarterly dividend, though insiders sold approximately $17.1 million worth of stock.

The health insurance sector is experiencing declining investor sentiment due to political changes and rising claims costs, despite its historical profitability. UnitedHealth Group, the largest health insurer by revenue, has seen its earnings negatively impacted by cyberattacks, increased utilization rates, and a higher medical loss ratio. However, recent regulatory developments and an improving medical loss ratio expected in 2026 could present a long-term investment opportunity.

RBC Capital has initiated coverage on Charles River Laboratories International Inc. (NYSE:CRL) with an Outperform rating and a price target of $215. The firm expects near-term growth and operating margin expansion, while also acknowledging potential technological disruption in the intermediate term. This outlook is supported by expected rises in 2026 operating margin estimates and the company's strong competitive position in preclinical R&D.

American Airlines pilots are now distributing collectible aircraft trading cards, a program initiated and funded by their union, the Allied Pilots Association, rather than the airline itself. This move, while popular with passengers, has sparked debate within the union over whether dues should cover a company branding effort. The unique situation highlights friction between labor and management regarding customer experience initiatives that traditionally fall under the airline's marketing budget.

The Rosen Law Firm is investigating potential securities claims against zSpace Inc. (NASDAQ: ZSPC) on behalf of investors who may have suffered losses due to allegedly misleading business information. The firm is preparing a class action lawsuit to recover investor losses, operating on a contingency fee basis. Shareholders are encouraged to contact The Rosen Law Firm to join the prospective class action.

An officer of Ambev S.A. (ABEV), Eduardo Braga Cavalcanti de Lacerda, sold 152,386 common shares in an open-market transaction on March 27, 2026, at a price of $2.85 per share. Following this sale, he directly holds 223,340 common shares of the company. This transaction is categorized as a moderate impact with negative sentiment according to Rhea-AI.